Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gallagher, H.
Right arrow Articles by Andrews, P. A
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

What is diabetic renal disease?

Hugh Gallagher

Peter A Andrews

SW Thames Renal & Transplantation Unit, St Helier Hospital, Carshalton, Surrey, SM5 1AA, UK, pandrews{at}sthelier.sghms.ac.uk

Diabetic nephropathy is the most common indication for long-term renal replacement therapy. In type 1 diabetes, it is rare after less than 10 or more than 35 years of disease, while the incidence in type 2 diabetes is related to the duration of diabetes. It is characterised histologically by mesangial expansion, glomerular basement membrane thickening, and glomerulosclerosis. Glomerular hyperfiltration is usual in the early stages of disease, and is thought to be an important mediator of the observed histological features. Hyperglycaemia-induced biochemical abnormalities, notably the formation of advanced glycation end products, overactivity of the polyol pathway, and protein kinase C activation, play a role in the pathogenesis; genetic factors are also implicated. Glycaemic control is of proven benefit in the early, often clinically silent stages of disease. When significant proteinuria and renal impairment have supervened, blood pressure control and reduction of proteinuria by means of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists are the most effective therapies to delay progression.

Key Words: type 2 diabetes • pathogenesis • clinical features.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 2, 96-100 (2002)
DOI: 10.1177/14746514020020020601
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?